FDA Meeting Preparation and Representation
Our services: FDA meetings
As part of our regulatory services in pharma, the Alira Health team can:
- Prepare and submit meeting request and packages to FDA for various Type A, Type B (Pre-IND and End-of-Phase Meetings) and Type C meetings with the FDA and analyze FDA responses
- Represent the sponsor at FDA meetings and in other correspondences with the FDA
- Advise our clients on regulatory options and potential pathways
- Conduct mock FDA meetings to prepare clients for FDA meetings
Why choose Alira Health?
As your partner, Alira Health supports your innovation, optimizing product development success every step of the way. Our integrated, collaborative teams provide a lifecycle approach to delivering our services, including:
- Regulatory strategy
- Regulatory intelligence
- Regulatory operations
- Market access
Opportunities and Challenges in the Therapeutic and CDMO Markets
Our Transaction Advisory experts have analyzed the CDMO industry trends, M&A activities, and projected growth in this CHEManager article.
Alira Health Named One of the World’s Best Management Consulting Firms by Forbes
Alira Health is proud to announce it has been named by Forbes as one of the World’s Best Management Consulting Firms for 2023.
The EU Pharmaceutical Package: Impact on Orphan Medicinal Products
This article reviews the proposed changes in the EU Pharma Package for data protection related to orphan medicinal products (OMPs).
Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets
Our Market Access experts have identified risks and opportunities associated with improving access to medicines in emerging countries.
What EU Companies Need to Know about the U.S. Inflation Reduction Act
We spoke with our inhouse experts to learn about the significance of the US Inflation Reduction Act for EU pharma and biotech companies.
Mid-size Pharma Accelerates Early Clinical Trial Engagement of Patients with A Rare Neurological Disease
A mid-size pharma company sought an experienced advisor who could help them engage patients for an open-label extension clinical study in a rare neurological disease.
The EU Pharmaceutical Package: Regulatory Protection Changes
Our regulatory experts present a more detailed analysis of the proposed changes introduced to Regulatory Data Protection (RDP).